SCHEMBL121772

SCHEMBL121772

O=C(Oc1ccc(Cl)c(Cl)c1Cl)Oc1ccc(Cl)c(Cl)c1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 1/20 0.49
MRGPRX4 Q96LA9 1/20 0.41
CYP3A4 P08684 2/20 0.41
MAPK1 P28482 1/20 0.41
TSHR P16473 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
LMNA P02545 4/20 0.35
NCEH1 Q6PIU2 2/20 0.35
TDP1 Q9NUW8 4/20 0.34
KDM4E B2RXH2 1/20 0.34
ALOX12 P18054 1/20 0.34
NPSR1 Q6W5P4 2/20 0.33
CSNK2A2 P19784 1/20 0.33
CSNK2B P67870 1/20 0.33
CSNK2A1 P68400 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30552290 1.00 FABP3 (0.49) FABP3MRGPRX4CYP3A4MAPK1TSHR
SCHEMBL11013172 0.90 FABP3 (0.43) FABP3MRGPRX4CYP3A4MAPK1TSHR
SCHEMBL2929232 0.86 FABP3 (0.49) FABP3MRGPRX4CYP3A4MAPK1TSHR
SCHEMBL31105888 0.84 FABP3 (0.51) FABP3MRGPRX4CYP3A4MAPK1TSHR
SCHEMBL121773 0.84 FABP3 (0.51) FABP3MRGPRX4CYP3A4MAPK1TSHR
SCHEMBL2849811 0.84 FABP3 (0.47) FABP3MRGPRX4CYP3A4MAPK1TSHR
SCHEMBL10911280 0.84 FABP3 (0.46) FABP3MRGPRX4TSHRNPC1RAB9A
SCHEMBL31612516 0.83 KDM4E (0.50) FABP3MRGPRX4CYP3A4MAPK1TSHR
SCHEMBL5790540 0.83 FABP3 (0.46) FABP3MRGPRX4CYP3A4MAPK1TSHR
SCHEMBL8860109 0.83 KDM4E (0.50) FABP3MRGPRX4CYP3A4MAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1706 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103068853-B Synergistic biomolecule-polymer conjugates PEG生物制药公司 2016-08-10 CN claimed
US-20160017058-A1 BISPECIFIC ANTIBODIES AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-01-21 US claimed
EP-2970505-A1 BISPECIFIC ANTIBODIES AND USES THEREOF The California Institute for Biomedical Research (US) 2016-01-20 EP claimed
WO-2014153002-A1 BISPECIFIC ANTIBODIES AND USES THEREOF THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2014-09-25 WO claimed
US-20100112660-A1 Method for Derivatization of Proteins Using Hydrostatic Pressure BAROFOLD, INC. (US) 2010-05-06 US claimed
WO-2009155102-A2 METHOD FOR DERIVATIZATION OF PROTEINS USING HYDROSTATIC PRESSURE BAROFOLD, INC. (US) 2009-12-23 WO claimed
EP-1200178-B1 COMPOSITE MEMBRANE WITH POLYALKYLENE OXIDE MODIFIED POLYAMIDE SURFACE DOW GLOBAL TECHNOLOGIES INC (US) 2008-11-12 EP claimed
EP-1493456-A2 Drug release stent coating and process Boston Scientific Scimed, Inc. (US) 2005-01-05 EP claimed
EP-1479401-A2 Drug release stent coating and process Boston Scientific Scimed, Inc. (US) 2004-11-24 EP claimed
EP-1200178-A1 COMPOSITE MEMBRANE WITH POLYALKYLENE OXIDE MODIFIED POLYAMIDE SURFACE THE DOW CHEMICAL COMPANY (US) 2002-05-02 EP claimed
US-6280853-B1 CROSSLINKED POLYAMIDES ON SUPPORTS WITH GRAFTING POLYOXYALKYLENE OXIDE GROUPS THE DOW CHEMICAL COMPANY 2001-08-28 US claimed
WO-2000076641-A1 COMPOSITE MEMBRANE WITH POLYALKYLENE OXIDE MODIFIED POLYAMIDE SURFACE THE DOW CHEMICAL COMPANY (US) 2000-12-21 WO claimed
EP-0832655-A2 Drug release stent coating and process SCHNEIDER (USA) INC. (US) 1998-04-01 EP claimed
JP-2153928-A None JP disclosed
JP-2153929-A None JP disclosed
EP-4104853-B1 ARGININE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI - PEG 20 ANTIBODIES FOR CANCER TREATMENT POLARIS GROUP (KY) 2026-05-06 EP disclosed
US-4001175-A ADDITIVES OF METAL SALTS OF SULFONIC ACIDS OF AROMATIC SULFOXIDES GENERAL ELECTRIC COMPANY (US) 1977-01-04 US disclosed
US-3971756-A SILOXANE, ORGANIC ALKALI OR ALKALINE EARTH SALTS GENERAL ELECTRIC COMPANY (US) 1976-07-27 US disclosed
US-3945967-A ALKYL PHOSPHITE, EPOXY COMPOUND GENERAL ELECTRIC COMPANY (US) 1976-03-23 US disclosed
US-3933730-A POLYDIMETHYLSILOXANE GUM, DIVIDED SILICA GENERAL ELECTRIC COMPANY (US) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160017058-A1 BISPECIFIC ANTIBODIES AND USES THEREOF FCGR3B, CD22, CD14 FABP3 1480/4885MRGPRX4 349/4885CYP3A4 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.